Boston Scientific 10-Q: Q3 Sales $5.14B, Net Income $582M After Cyberattack Hit
BSX is trading near its 52-week low of $39.57 (12% above the low).
Summary
Boston Scientific's Q3 10-Q confirms $5.14B of sales and $582M of net income, with the cyberattack cutting gross margin to 66.7%. It also details $1.5B of MiRus investment, a $250M TingSN deal and a Penumbra close now expected in early 2027.
Key Events · Earnings and Guidance · BSX
-
Q3 Sales $5.14B, Net Income $582M
Net sales rose 1.5% to $5,138M from $5,065M, but net income attributable to common stockholders fell 22.9% to $582M and diluted EPS dropped to $0.40 from $0.51.
-
Cyberattack Cuts Gross Margin to 66.7%
Gross margin fell from 69.9% a year ago, with 1.7 points from abnormal production variances tied to the August cybersecurity incident; litigation-related net charges added $81M in the quarter and $157M for the nine months.
-
Cash Falls to $609M, $1.03B Commercial Paper
Cash and cash equivalents dropped to $609M from $1,965M at December 31, 2025, while $1,029M of commercial paper was outstanding against a $2,750M program; leverage was 1.95x versus a 3.75x covenant limit.
-
MiRus Deal: $1.5B Equity Plus $3.0B Option
Boston Scientific paid $1.5B for ~33.75% of MiRus plus an exclusive option to buy its TAVR business for up to $3.0B more; a separate October 2, 2026 Blackstone agreement funds up to $455M of VITALYST development.
Analysis · BSX · Industrial Applications And Services
The headline numbers were already out on October 28, but the full 10-Q fills in what the earnings release did not. Gross margin fell to 66.7% from 69.9% a year ago, with 1.7 points of that from idle production during the August cyberattack, and litigation charges of $81M landed in the quarter. The filing also details a heavy capital deployment slate: $1.5B into MiRus plus a $3.0B TAVR option, a $250M TingSN deal, and a Blackstone agreement to fund up to $455M of VITALYST development. That spending comes against cash that has dropped to $609M from $1.965B at year-end, backstopped by $1.029B of commercial paper. The Penumbra close has slipped to early 2027, with roughly $11.0B of cash and new debt plus stock still to be raised.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BSX was trading at $44.24 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $64.2B. The 52-week trading range was $39.57 to $105.65. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.